Jan Östergren
Impact in
- Cardiology and Cardiovascular Medicine top 0.05%
- Blood Pressure and Hypertension Studies
- Heart Failure Treatment and Management
- Renin-Angiotensin System Studies
- Cardiovascular Function and Risk Factors
- Cardiovascular Health and Disease Prevention
-
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes Treatment and Management
Papers in
-
- Heart Failure Treatment and Management 36
- Blood Pressure and Hypertension Studies 34
- Atrial Fibrillation Management and Outcomes 7
-
- Diabetes, Cardiovascular Risks, and Lipoproteins 10
- Diabetes Treatment and Management 8
- Co-authors
- Salim Yusuf (31 shared papers)Karl B Swedberg (27 shared papers)John J.V. McMurray (28 shared papers)Christopher Bull Granger (27 shared papers)Eric L. Michelson (25 shared papers)Marc Alan Pfeffer (22 shared papers)Bertil Olofsson (17 shared papers)Peter Held (7 shared papers)
- Journals
- European Heart Journal (10 papers)The Lancet (8 papers)Journal of Internal Medicine (8 papers)Blood Pressure (8 papers)Journal of Hypertension (7 papers)
- Partner nations
- SwedenUnited KingdomUnited States
In The Last Decade
Jan Östergren
153 papers receiving 33.1k citations
Jan Östergren's Hit Papers
Peers
Comparison fields: 5 of 164
- Cardiology and Cardiovascular Medicine 22k
- Endocrinology, Diabetes and Metabolism 3.8k
- Family Practice 402
- Nephrology 1.3k
- Surgery 4.9k
Countries citing papers authored by Jan Östergren
This map shows the geographic impact of Jan Östergren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Östergren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Östergren more than expected).
Fields of papers citing papers by Jan Östergren
This network shows the impact of papers produced by Jan Östergren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Östergren. The network helps show where Jan Östergren may publish in the future.
Co-authors
The 25 scholars most cited alongside Jan Östergren, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 154 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2013 ESH/ESC Guidelines for the management of arterial hypertension Hit paper breakdown → | 2013 | 8816 |
| 2 | Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Hit paper breakdown → | 2003 | 3003 |
| 3 | Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Hit paper breakdown → | 2003 | 2380 |
| 4 | Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Hit paper breakdown → | 2005 | 2184 |
| 5 | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Hit paper breakdown → | 2003 | 2037 |
| 6 | ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Hit paper breakdown → | 2013 | 1618 |
| 7 | Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Hit paper breakdown → | 2003 | 1499 |
| 8 | Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Hit paper breakdown → | 2003 | 1320 |
| 9 | Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary Hit paper breakdown → | 2007 | 1317 |
| 10 | ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Hit paper breakdown → | 2011 | 1163 |
| 11 | CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL Hit paper breakdown → | 2003 | 902 |
| 12 | Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure Hit paper breakdown → | 2006 | 806 |
| 13 | Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme Hit paper breakdown → | 2008 | 558 |
| 14 | ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) Hit paper breakdown → | 2014 | 536 |
| 15 | 2001 | 382 | |
| 16 | CHARM INVESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND PRESERVED LEFT-VENTRICULAR EJECTION FRACTION: THE CHARM-PRESERVED TRIAL | 2003 | 369 |
| 17 | 2004 | 324 | |
| 18 | 2005 | 293 | |
| 19 | 1999 | 252 | |
| 20 | 2003 | 250 |
About Jan Östergren
Jan Östergren is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery, Physiology and Emergency Medical Services, having authored 154 papers that have together received 35.8k indexed citations. Recurring topics across this work include Heart Failure Treatment and Management (36 papers), Blood Pressure and Hypertension Studies (34 papers), Peripheral Artery Disease Management (17 papers), Blood properties and coagulation (13 papers), Thermoregulation and physiological responses (12 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers), Diabetes Treatment and Management (8 papers) and Atrial Fibrillation Management and Outcomes (7 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (22k citations), Endocrinology, Diabetes and Metabolism (3.8k citations), Family Practice (402 citations), Nephrology (1.3k citations) and Surgery (4.9k citations). Jan Östergren has collaborated with scholars based in Sweden, United Kingdom and United States. Frequent co-authors include Salim Yusuf, Karl B Swedberg, John J.V. McMurray, Christopher Bull Granger, Eric L. Michelson, Marc Alan Pfeffer, Bertil Olofsson, Peter Held, Hans Wedel and Neil R Poulter. Their work appears in journals such as European Heart Journal, The Lancet, Journal of Internal Medicine, Blood Pressure and Journal of Hypertension.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.